NY-ESO-1 Vaccine in Combination With Ipilimumab in Patients With Unresectable or Metastatic Melanoma
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Craig L Slingluff, MD
University of Virginia
Principal Investigator - Hassane M Zarour, MD
University of Pittsburgh
Principal Investigator - Jonathan Cebon, MBBS, FRACP, PhD
Austin Health, Ludwig Oncology Unit
Principal Investigator - Michael A Postow, MD
Memorial Sloan Kettering Cancer Center
Study Chair - Philip Friedlander, MD
Icahn School of Medicine at Mount Sinai
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
5 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Austin Health, Ludwig Oncology Unit
Melbourne, Victoria, Australia
- Memorial Sloan-Kettering Cancer Center
New York, New York, United States
- Mount Sinai Medical Center
New York, New York, United States
- University of Pittsburgh Cancer Center
Pittsburgh, Pennsylvania, United States
- University of Virginia Cancer Center
Charlottesville, Virginia, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 24 Jan 2014
- Primary completion
- 17 May 2016
- Completion
- 17 May 2016
- Last update posted
- 12 Oct 2022
- Registered enrollment
- 8
- Registry id
- NCT01810016
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.